parC mutations in fluoroquinolone-resistant Borrelia burgdorferi.
Article Details
- CitationCopy to clipboard
Galbraith KM, Ng AC, Eggers BJ, Kuchel CR, Eggers CH, Samuels DS
parC mutations in fluoroquinolone-resistant Borrelia burgdorferi.
Antimicrob Agents Chemother. 2005 Oct;49(10):4354-7.
- PubMed ID
- 16189120 [ View in PubMed]
- Abstract
We have isolated in vitro fluoroquinolone-resistant mutants of the Lyme disease agent, Borrelia burgdorferi. Mutations in parC, which encodes a subunit of topoisomerase IV, were associated with loss of susceptibility to sparfloxacin, moxifloxacin, and Bay-Y3118, but not ciprofloxacin. This is the first description of fluoroquinolone resistance in the spirochete phylum.
DrugBank Data that Cites this Article
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Sparfloxacin DNA topoisomerase 4 subunit A Protein Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) YesInhibitorDetails